23
Participants
Start Date
February 27, 2024
Primary Completion Date
July 17, 2025
Study Completion Date
July 17, 2025
Ruxolitinib Cream 1.5%
Ruxolitinib Cream 1.5%
Equity Medical, Llc, New York
Paddington Testing Co Inc, Philadelphia
Advanced Pharma Cr, Llc, Miami
Sullivan Dermatology North Miami Beach Office, North Miami Beach
Olympian Clinical Research, Tampa
International Clinical Research Tennessee Llc, Murfreesboro
Equity Medical, Bowling Green
Dawes Fretzin Clinical Research Group Llc, Indianapolis
Revival Research Institute, Llc Troy, Troy
Oakland Hills Dermatology Pc, Auburn Hills
Red River Research Partners, Fargo
Central Sooner Research, Oklahoma City
North Texas Center For Clinical Research Ntccr, Frisco
Dermresearch, Inc., Austin
St Lukes Clinic Dermatology Ketchum, Ketchum
Saguaro Dermatology, Phoenix
Affiliated Dermatology, Scottsdale
Clinical Science Institute Clinical Research Specialists Inc, Santa Monica
Amicis Research Center Valencia, Northridge
First Oc Dermatology, Fountain Valley
Lead Sponsor
Incyte Corporation
INDUSTRY